study design, size, duration: This was a retrospective analytical study performed in the Centre for Reproductive Medicine, at St Bartholomew's Hospital, between January 2000 and December 2014. The aim of this study was to analyse the response to ovarian stimulation in cancer patients before undergoing cancer treatment and to determine whether any difference can be attributed to underlying cancer diagnosis. We also report the pregnancy outcomes.
Introduction
Advances in early detection of cancer and improved treatment protocols have increased patient survival significantly. The incidence of cancer in reproductive age women reported is 7% and the 5-year survival rate for them has increased during the last few years (Horner et al., 2011) . Thousands of cancer survivors are women of reproductive age (Howlader et al., 2015) . This, together with the trending of delayed childbearing, is resulting in a higher number of women diagnosed with cancer before their first pregnancy (Martin et al., 2006) .
The negative effect of cancer therapy on fertility is well known. Some chemotherapeutic agents, abdominal or pelvic radiotherapy, bone marrow transplantation and surgery for gynaecological malignancies have a high risk of gonadal damage (Noyes et al., 2011a,b; Morgan et al., 2012) . It has been estimated that around 42% of female cancer patients in reproductive age may develop premature ovarian failure as consequence of cancer therapy (Larsen et al., 2003; Eskander et al., 2011) .
The impact of cancer therapy on future fertility has raised concerns and fertility preservation (FP) is becoming an important component in the management of cancer patients (Lee et al., 2006; Jeruss and Woodruff, 2009 ). The most common malignancy in patients undergoing FP is breast cancer (Jemal et al., 2009; Horner et al., 2011) . It is known that the loss of the reproductive capacity negatively impacts the quality of life (Tschudin and Bitzer, 2009; Reh et al., 2011; Letourneau et al., 2012) . The American Society of Clinical Oncology guidelines recommend that oncology patients in reproductive age should be counselled on the options for FP and future reproduction prior to the initiation of gonadotoxic therapy (Lee et al., 2006; Loren et al., 2013) .
There are several strategies for FP in patients with cancer, including preservation of gametes, embryos or gonadal tissue for their use in the future, but a lack of knowledge exists in terms of outcomes (Ethics Committee of ASRM, 2013). Cryopreservation of mature oocyte is currently one of the major approaches with acceptable pregnancy rates, providing real options for oncological patients of adolescent age or women who do not have a male partner (Grifo et al., 2006; Grifo and Noyes, 2010) . In vitro maturation of oocytes or ovarian tissue cryopreservation for future retransplantation may be alternative options when other more established methods are not feasible (Huang et al., 2008; Ethics Committee of ASRM, 2013; De Vos et al., 2014) . Combination of different treatments may improve the success rates (González et al., 2011) .
Most women that undergo FP before cancer therapy have no history of infertility and their ovarian response may be difficult to predict. The individual ovarian reserve can be measured by serological and ultrasound markers, mainly antral follicle count (AFC). The most commonly used assessment is the serum FSH and estradiol levels on early days of the menstrual cycle. Anti-Müllerian hormone is also used for the estimation of the ovarian reserve. To minimize the delays of cancer therapy antagonist protocols are the most commonly used, which has a shorter time to start of stimulation (von Wolff et al., 2009) . Aromatase inhibitors (Letrozole) are usually added in patients with hormone-dependent cancers to limit exogenous estrogen exposure .
Some studies have suggested a negative effect of the oncological disease on the ovarian function even before starting cancer treatment (Agarwal and Said, 2004; Quintero et al., 2010; Domingo et al., 2012; Friedler et al., 2012) . Pal et al. (1998) were the first reporting an adverse influence of malignancy on oocyte quality. However, other studies have found no significant impact in ovarian reserve or response to stimulation in patients with cancer (Knopman et al., 2009; Das et al., 2011; Robertson et al., 2011; Tulandi and Holzer, 2012) . Data regarding this subject are conflicting and the potential adverse effect of the cancer process itself remains unknown.
Fertility outcomes in oncology patients have not been adequately studied given the small number of patients with cancer undergoing FP. Many studies have reported the results of ovarian stimulation for FP, but only few of them have reported the pregnancy outcomes of patients returned to use their embryos or oocytes after cancer therapy, which would be the real important outcome after all. The aim of this study is to analyse the response to ovarian stimulation in women recently diagnosed with cancer before undergoing cancer treatment to determine whether any difference can be attributed to underlying cancer diagnosis and to report the pregnancy outcomes after cancer treatment.
Materials and Methods

Population
A total of 531 female patients were referred for counselling on FP to St Barthomew's Hospital since the start of the FP program for cancer patients in 2000. A total of 306 patients underwent ovarian stimulation for oocyte or embryo cryopreservation before cancer therapy. Two hundred and twenty-five patients (42.4%) did not undergo FP.
None of the patients undergoing FP had exposure to chemotherapy or radiotherapy prior to ovarian stimulation. Five patients with ovarian cancer and six patients with borderline ovarian tumours underwent ovarian surgery prior to ovarian stimulation, which was unilateral oophorectomy with or without contralateral ovarian cystectomy, and were planning chemotherapy or completion surgery after FP. Of nine patients with endometrial cancer, five were on conservative management of their cancer with hormonal treatment and four underwent a hysterectomy with conservation of ovaries before FP and were planning surrogacy. Of 22 patients with cervical cancer, 6 underwent radical hysterectomy with ovarian conservation before FP, the rest were planning trachelectomy or chemoradiation after ovarian stimulation. Patients on other categories were planning chemotherapy after FP.
The data were collected retrospectively from medical records including the year of referral, age, parity, the type of cancer, BMI, AFC, FSH level, stimulation protocol, stimulation length, dose of gonadotrophin used, number of oocytes retrieved, number of mature oocytes retrieved, fertilization rate, number of cycles cancelled, patients returned after cancer therapy, number of embryos transferred, pregnancy test result and the pregnancy outcome.
Stimulation protocol
All patients underwent ovarian reserve estimation before ovarian stimulation with measurements of basal FSH level in the early follicular phase of the cycle and transvaginal ultrasound scan for AFC. Ovarian stimulation was performed using the following protocols: GnRH antagonist suppression protocol (Cetrotide), short flare protocol or luteal phase GnRH agonist downregulation. Letrozole 5 mg was added in patients with hormone-dependent cancers. Recombinant FSH (Gonal-F) or urinary human menopausal gonadotrophin (Menopur) was started during the early follicular phase of the cycle. Protocols have been previously explained elsewhere (Michaan et al., 2010; Domingo et al., 2012) . Final oocyte maturation was triggered with recombinant human chorionic gonadotrophin 250 mg (Ovitrelle) when 2 -3 follicles reached 18 mm in diameter. Transvaginal ultrasound guided oocyte retrieval was performed 36 h after trigger. Oocytes were either cryopreserved or fertilized. Oocytes were fertilized using IVF or ICSI until 2010, then as per clinical protocol, ICSI was always performed for cancer patients, to diminish a situation of failure of fertilization, and embryos were cryopreserved using slowfreezing technique.
For patients who have successfully survived and have returned to attempt pregnancy, hormonal therapy was used for endometrial preparation before embryo transfer. After pituitary down-regulation with GnRH, patients commenced on estradiol valerate 2 mg 12 hourly or E 2 patches 200 mg alternate days. The endometrium was monitored with ultrasound scan and the dose of E 2 was increased from Day 8 if endometrium was ,7 or ,8 mm on Day 11. Embryo transfer was performed on Days 16 and 17 if the endometrium was ≥8 mm with triple line, and Crinone Gel 8% daily was added to E 2 until 14 days after transfer, continuing until 12 weeks of gestation if positive pregnancy test.
Statistical analysis
We compared the baseline characteristics and ovarian response in five subgroups of cancer patients: breast, haematological, gynaecological, gastrointestinal and other cancers. The main outcome was the number of mature oocytes retrieved and pregnancy outcomes. Secondary outcomes included total dose of gonadotrophin used, total number of oocytes retrieved and fertilization rate. Patients with ovarian cancer or borderline ovarian tumours were excluded from the final analysis as they underwent ovarian surgery before ovarian stimulation, and this may compromise the ovarian reserve and explain a lower ovarian response.
Data were collected and analysed using SPSS (Statistical Program for Social Sciences) version 17.0. We used the Kolmorov-Smirnov test to evaluate the distribution of the data. The x 2 test was used to compare categorical data when data were normally distributed. We used Student's t-test for pair-wise comparison. When the data were not normally distributed the MannWhitney U test was used for bivariate comparison. Analysis of variance (ANOVA), Kruskal -Wallis and x 2 tests were performed when appropriate to compare the results between different groups of cancer. P , 0.05 was used to determine significance.
Ethical approval
Our study was exempt from institutional review board ethical approval from an NHS Research Ethic Committee, because it qualifies under a category outlined in the UK Health Departments' Governance Arrangements for Research Ethics Committees (REC). Research limited to secondary use of information previously collected in the course of normal care is generally excluded from REC review. This exception also applies to research undertaken by staff within a care team using information previously collected in the course of care for their own patients (Governance Arrangements for Research Ethics Committees (GAfREC, 2011)). chemotherapy. Twenty-four patients were considered to be not suitable for FP due to medical reasons, poor cancer prognosis or were clinically too unwell at the moment of the consultation to receive ovarian stimulation. Sixteen patients had chemotherapy previously or were undergoing cancer treatment during the referral for FP. The rest of the patients decided not to undergo FP for personal choice or unknown reasons.
The main cancer diagnosis was breast cancer in 145 patients (47.4%); 79 patients (25.8%) had haematological malignancies; 42 (13.7%) had gynaecological malignancies; 20 had gastrointestinal cancer (6.5%) and 20 (6.5%) had other type of malignancies (Table I) .
The stimulation protocols performed were GnRH antagonist suppression in the majority of patients, 241 (78.75%). One hundred and thirty four patients with breast cancer received Letrozole as part of the antagonist protocol. Flare protocol was followed in 52 (17%) and the luteal phase GnRH agonist down-regulation was used in 13 (4.25%). One hundred and ninety-eight patients (64.7%) decided to freeze embryos, 104 (34%) chose to freeze oocytes and 4 (1.3%) cryopreserved both oocytes and embryos. Fifty-one patients (16.7%) had children previously. Table II summarizes the subcategory analyses of baseline characteristics and ovarian response by the type of cancer category. Patients with breast cancer were significantly older than patients in other groups (P , 0.001). There were no differences on the dose of gonadotrophins used for stimulation and on the duration of stimulation between the groups. There was a significant difference on the number of matured oocytes retrieved, with a higher number in patients with haematological malignancies (P ¼ 0.003). Patients with gynaecological cancer had lessmature oocytes retrieved compared with haematological and breast cancer patients (P ¼ 0. Fertility preservation in female oncology patients subcategories analysis the number of oocytes obtained was analysed by the age group, a significant difference was found in patients between the age groups of 31 -35 years (P ¼ 0.026). The mean number of embryos frozen was 7.5 + 5, with a maximum of 27 embryos in a 31-year-old patient with breast cancer, who had a severe ovarian hyper-stimulation syndrome (OHSS). The number of embryos cryopreserved was higer in patients with haematological malignancies (P ¼ 0.006). The fertilization rate and the number of cycles cancelled were comparable between all the groups. Overall, 8 cycles were cancelled (2.6%) due to lack of response to gonadotrophins, including one patient with ovarian cancer. In 11 cycles, no embryos were obtained due to failed fertilization (3.6%). Five cases of failed fertilization (45.5%) happened before 2010, and six cases after 2010, when ICSI was performed routinely for all FP patients. When performing regression analysis on failed fertilization controlling for age, and the date of procedure (before and after 2010), the age of the patient and the year of the procedure do not have influence on fertilization rate. There were three cases of moderate to severe OHSS, all of them resolved with conservative management not resulting in delay of chemotherapy.
Thirty-two embryo transfer cycles have been done in 22 cancer patients who have returned to attempt pregnancy after overcoming their disease. Mean time interval between the ovarian stimulation to the first embryo transfer cycle was 31 months. Twelve women were planned initially for surrogacy; the most common reason was hysterectomy for gynaecological malignancy or advice against pregnancy by oncologist for medical reasons. Two of them have returned and underwent embryo transfer in a gestational carrier. Pregnancy rate per transfer cycle was 43.75%, and cumulative pregnancy rate per patient was 54.5%. The miscarriage rate was 57.1% per pregnancy; therefore, the cumulative live birth rate per transfer was 18.75%, and the live birth rate per patient was 22.72%. A total of 8-term healthy babies have been born. Pregnancy outcomes are shown in Table III . Apart from that, four pregnancies by natural conception have been noted. Overall, 147 patients (48%) have embryos currently remaining in storage and 92 (30%) still have cryopreserved oocytes.
Discussion
The number of patients with cancer referred for counselling on FP has increased over the time since the start of the FP program at St Bartholomew's Hospital in 2000, with a maximum of 82 patients referred in 2012. Cancer treatment may affect ovarian function for different reasons. Chemotherapy can cause ovarian failure damaging oocytes. The extent of damage depends on type of medication, dosage and patient age (Knopman et al., 2010; Morgan et al., 2012) . Irradiation of abdomen and pelvis can cause a dose-dependent reduction of the ovarian reserve (Wo and Viswanathan, 2009 ). Pelvic surgery can have an important impact on fertility due to adhesions or the removal of the ovaries; therefore, FP would be indicated in patients with gynaecological cancers primarily amenable to conservative surgery, even when chemoor radiotherapy is not needed (Alvarez and Vazquez-Vicente, 2015) .
In our study, patients with breast cancer were significantly older than patients in other groups. Patients with haematological malignancies were younger; this could be explained by the fact that 65.8% of the patients in this group were diagnosed with Hodgkin's Lymphoma, which is diagnosed mostly in young adults (Howlader et al., 2015) . Baseline FSH, total dose of gonadotrophins used for stimulation and the number of days of stimulation were comparable between the groups.
Most of the published studies have not demonstrated significant differences on ovarian reserve and oocytes retrieved between cancer patients and the control group (Knopman et al., 2009; Quintero et al., 2010; Das et al., 2011; Moria et al., 2011; Noyes et al., 2011a,b; Robertson et al., 2011; Almog et al., 2012; Johnson et al., 2013; Levin and Almog, 2013; Nurudeen et al., 2016; Cardozo et al., 2015) . Devesa et al. (2014) compared the ovarian response in 48 oncology patients with the expected one according to an age-specific nomogram showed that ovarian response in patients with cancer is as expected by age. Other authors have found a lower response in women with cancer (Quintero et al., 2010; Domingo et al., 2012; Garcia-Velasco et al., 2013) and a significant relationship between the age of the patients and the total number of oocytes and embryos cryopreserved (Lawrenz et al., 2010 Only few studies have analysed types of cancer separately. In the present study, patients with haematological malignancies had the best response with more mature oocytes retrieved and more embryos cryopreserved; this may be influenced by the age of the patients. However, patients with breast cancer even being older than other groups, also had a good response. We found a lower response to ovarian stimulation in patients with gynaecological cancer. One factor that we need to take into account is the fact that 10 patients in this group underwent a hysterectomy with conservation of ovaries before FP, whether this type of surgery affects the ovarian response to stimulation is unclear.
In contrast to our results, Pavone et al. found that women with gynaecological malignancies tended to have a better ovarian response. But they included 14 women with the previous exposure to chemotherapy (Pavone et al., 2014) . Almog et al. (2012) in their study with 81 patients concluded that the ovarian reserve was not influenced by type of cancer. Moria et al. (2011) found that patients with breast cancer had less oocytes retrieved than the control group. More cases are needed in order to determine whether any difference in treatment outcome could be attributed to a specific cancer. Oktay et al. (2010) stated that BRCA1 mutation carriers had a poorer response to ovarian stimulation due to the association with occult primary ovarian insufficiency. In our study, unfortunately only few patients with breast cancer underwent genetic test for the detection of BRCA1 mutation; therefore, we cannot make any conclusion on that.
The present study is one of the largest series in the literature reporting pregnancy outcomes in cancer patients seeking FP. Most studies have shown preliminary results only, with small number of patients (Table IV) . Twenty-two patients returned to attempt pregnancy and 32 embryo transfer cycles were performed. Pregnancy rate per transfer was 43.75% and the cumulative pregnancy rate per patient was 54.5%, which match most IVF unit's results. To calculate the realistic live birth rate miscarriage rate must be included. The miscarriage rate in our series was 57.1% per pregnancy, and live birth rate per patient was 22.72%. We think that the slow freezing used may have an impact on this high miscarriage rate. There were two cases that are important to comment; the first one is a patient with cervical cancer treated with radical trachelectomy 5 months before embryo transfer, which is an important risk factor for late miscarriage and premature labour. She had a miscarriage of a twin pregnancy at 22 weeks. The second one is a patient with endometrial cancer treated with conservative management that had two miscarriages after embryo transfer; a poor quality of the endometrium could influence on these results. Another factor to take into consideration in the rest of patients is the previous exposure to chemotherapy. To our knowledge, none of the patients underwent pelvic radiotherapy prior to embryo transfer.
Our study has some limitations. Patients were included over 15 years, and over that time technology has changed and protocols have evolved. The subcategories analysis should be interpreted with caution, as in each subgroup there are different types of malignancies, they are different concerning number of patients in different age groups, and different stimulation protocols were applied. Only few patients have come back to attempt pregnancy after being cured from their disease. We do not routinely follow-up these patients; therefore, we are unable to report the reason for non-return for embryo transfer. In addition, we cannot report information on spontaneous conceptions and births. Slow freezing, high miscarriage rate and low live birth rate per transfer are other limitations of this study. The main strength of our study is the large sample size and that this is the largest series analysing different types of cancer separately.
Further studies when more of these patients return to attempt pregnancy are needed to determine long-term outcomes, clinical implications and potential success rates. To provide precise information in this field is invaluable, as young patients with cancer will not only be concerned with cure and survival, preservation of fertility will be an important issue for their quality of life.
In conclusion, ovarian stimulation outcomes in this study are acceptable with similar results to previous studies. The main difference between cancer groups is the number of mature oocytes retrieved, being lower in patients with gynaecological cancer. Only few patients have returned to attempt pregnancy so far. The fertility and pregnancy outcomes of our study will provide valuable information for doctors to counsel the oncology patients appropriately regarding FP before cancer treatment. Cancer diagnosis and urgency to start the cancer treatment should be considered when making stimulation decisions in this population.
